Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Thorén FB[au]:

Search results

Items: 43

1.

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.

Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K.

Hum Vaccin Immunother. 2019 Jul 24:1-3. doi: 10.1080/21645515.2019.1636598. [Epub ahead of print]

PMID:
31242079
2.

The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Blood. 2019 Mar 28;133(13):1479-1488. doi: 10.1182/blood-2018-09-874990. Epub 2019 Jan 15.

3.

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.

4.

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Kiffin R, Grauers Wiktorin H, Nilsson MS, Aurelius J, Aydin E, Lenox B, Nilsson JA, Ståhlberg A, Thorén FB, Hellstrand K, Martner A.

Front Oncol. 2018 Jun 18;8:218. doi: 10.3389/fonc.2018.00218. eCollection 2018.

5.

Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.

Wenger A, Werlenius K, Hallner A, Thorén FB, Farahmand D, Tisell M, Smits A, Rydenhag B, Jakola AS, Carén H.

Neoplasia. 2018 Jan;20(1):25-31. doi: 10.1016/j.neo.2017.10.006. Epub 2017 Dec 1.

6.

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Sander FE, Nilsson M, Rydström A, Aurelius J, Riise RE, Movitz C, Bernson E, Kiffin R, Ståhlberg A, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484. doi: 10.1007/s00262-017-2040-9. Epub 2017 Jul 18.

7.

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Leukemia. 2017 Dec;31(12):2552-2559. doi: 10.1038/leu.2017.151. Epub 2017 May 22.

8.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

9.

NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.

Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, Hansson M, Martner A, Thorén FB, Hellstrand K.

J Leukoc Biol. 2017 Aug;102(2):459-466. doi: 10.1189/jlb.5VMA1116-454R. Epub 2017 Mar 14.

PMID:
28292946
10.

Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.

Rydström A, Hallner A, Aurelius J, Sander FE, Bernson E, Kiffin R, Thoren FB, Hellstrand K, Martner A.

J Leukoc Biol. 2017 Aug;102(2):467-474. doi: 10.1189/jlb.5VMA1116-455R. Epub 2017 Feb 24.

PMID:
28235771
11.
12.

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.

Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.

Oncotarget. 2016 May 31;7(22):32046-53. doi: 10.18632/oncotarget.8769.

13.

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.

14.

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.

Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Oncotarget. 2016 Feb 16;7(7):7586-96. doi: 10.18632/oncotarget.7210.

15.

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.

Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncotarget. 2015 Dec 15;6(40):42569-74. doi: 10.18632/oncotarget.5559.

16.

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.

Riise RE, Bernson E, Aurelius J, Martner A, Pesce S, Della Chiesa M, Marcenaro E, Bylund J, Hellstrand K, Moretta L, Moretta A, Thorén FB.

J Immunol. 2015 Aug 1;195(3):1121-8. doi: 10.4049/jimmunol.1500709. Epub 2015 Jun 17.

17.

Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase.

Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, Thorén FB, Ståhlberg A, Hermodsson S, Hellstrand K.

J Immunol. 2015 May 15;194(10):5014-21. doi: 10.4049/jimmunol.1402991. Epub 2015 Apr 13.

18.

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia.

Hallner A, Aurelius J, Thorén FB, Sander FE, Brune M, Hellstrand K, Martner A.

Eur J Haematol. 2015 Mar;94(3):279-80. doi: 10.1111/ejh.12454. Epub 2014 Nov 21. No abstract available. Erratum in: Eur J Haematol. 2019 Jan;102(1):99.

PMID:
25256820
19.

CD20 antibodies induce production and release of reactive oxygen species by neutrophils.

Werlenius O, Riise RE, Simpanen M, Aurelius J, Thorén FB.

Blood. 2014 Jun 19;123(25):4001-2. doi: 10.1182/blood-2014-05-574285. No abstract available.

20.

Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes.

Akhiani AA, Werlenius O, Aurelius J, Movitz C, Martner A, Hellstrand K, Thorén FB.

PLoS One. 2014 Feb 21;9(2):e89646. doi: 10.1371/journal.pone.0089646. eCollection 2014.

21.

Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.

Thorén FB, Anderson H, Strannegård Ö.

Cancer Immunol Immunother. 2013 Oct;62(10):1547-51. doi: 10.1007/s00262-013-1458-y. Epub 2013 Aug 24.

PMID:
23979447
22.

Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Hellstrand K.

Blood Rev. 2013 Sep;27(5):209-16. doi: 10.1016/j.blre.2013.06.006. Epub 2013 Jul 18. Review.

PMID:
23871358
23.

A simple skin blister technique for the study of in vivo transmigration of human leukocytes.

Davidsson L, Björkman L, Christenson K, Alsterholm M, Movitz C, Thorén FB, Karlsson A, Welin A, Bylund J.

J Immunol Methods. 2013 Jul 31;393(1-2):8-17. doi: 10.1016/j.jim.2013.03.013. Epub 2013 Apr 6.

PMID:
23570945
24.

Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes.

Aurelius J, Martner A, Riise RE, Romero AI, Palmqvist L, Brune M, Hellstrand K, Thorén FB.

J Leukoc Biol. 2013 Jan;93(1):155-60. doi: 10.1189/jlb.0512257. Epub 2012 Oct 16.

PMID:
23072905
25.

Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.

Aurelius J, Martner A, Brune M, Palmqvist L, Hansson M, Hellstrand K, Thoren FB.

Haematologica. 2012 Dec;97(12):1904-8. doi: 10.3324/haematol.2012.066399. Epub 2012 Jun 11.

26.

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.

Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K, Martner A.

Blood. 2012 Jun 14;119(24):5832-7. doi: 10.1182/blood-2011-11-391722. Epub 2012 May 1.

27.

Analyzing cell death events in cultured leukocytes.

Christenson K, Thorén FB, Bylund J.

Methods Mol Biol. 2012;844:65-86. doi: 10.1007/978-1-61779-527-5_5.

PMID:
22262435
28.

Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism.

Thorén FB, Riise RE, Ousbäck J, Della Chiesa M, Alsterholm M, Marcenaro E, Pesce S, Prato C, Cantoni C, Bylund J, Moretta L, Moretta A.

J Immunol. 2012 Feb 15;188(4):1668-74. doi: 10.4049/jimmunol.1102002. Epub 2012 Jan 9.

29.

Redox remodeling by dendritic cells protects antigen-specific T cells against oxidative stress.

Martner A, Aurelius J, Rydström A, Hellstrand K, Thorén FB.

J Immunol. 2011 Dec 15;187(12):6243-8. doi: 10.4049/jimmunol.1102138. Epub 2011 Nov 16.

30.

Antitumor properties of histamine in vivo.

Thoren FB, Aurelius J, Martner A.

Nat Med. 2011 May;17(5):537; author reply 537-8. doi: 10.1038/nm0511-537a. No abstract available.

PMID:
21546964
31.

Adjuvant interferon: extended follow-up times needed?

Thoren FB, Strannegård Ö.

Lancet Oncol. 2011 May;12(5):419. doi: 10.1016/S1470-2045(11)70107-3. No abstract available.

PMID:
21536217
32.

[The discussion about Multiferon should go on].

Strannegård O, Thorén FB.

Lakartidningen. 2010 Dec 15-21;107(50):3227; discussion 3227. Swedish. No abstract available.

PMID:
21294341
33.

[Underutilization of anticancer agents--an example].

Strannegård O, Thorén FB.

Lakartidningen. 2010 Dec 8-14;107(49):3150; discussion 3150-1. Swedish. No abstract available.

PMID:
21280349
34.

Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K.

Expert Rev Hematol. 2010 Aug;3(4):381-91. doi: 10.1586/ehm.10.30. Review.

PMID:
21083028
35.

The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1.

Thorén FB, Karlsson J, Dahlgren C, Forsman H.

Biochem Pharmacol. 2010 Aug 1;80(3):389-95. doi: 10.1016/j.bcp.2010.04.009. Epub 2010 Apr 13.

PMID:
20394736
36.

Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.

Romero AI, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K.

Scand J Immunol. 2009 Sep;70(3):194-205. doi: 10.1111/j.1365-3083.2009.02303.x. Review.

37.

Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.

Thorén FB, Romero AI, Brune M, Hellstrand K.

Expert Opin Biol Ther. 2009 Sep;9(9):1217-23. doi: 10.1517/14712590903130566. Review.

PMID:
19653866
38.

[Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate].

Strannegärd O, Thorén FB, Lundgren E.

Lakartidningen. 2008 Feb 6-12;105(6):358-61. Review. Swedish. No abstract available.

PMID:
18380352
39.

The CD16-/CD56bright subset of NK cells is resistant to oxidant-induced cell death.

Thorén FB, Romero AI, Hermodsson S, Hellstrand K.

J Immunol. 2007 Jul 15;179(2):781-5.

41.

Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes.

Thorén FB, Romero AI, Hellstrand K.

J Immunol. 2006 Jun 15;176(12):7301-7.

42.
43.

Supplemental Content

Loading ...
Support Center